



ATOPIC ECZEMA/DERMATITIS

BASELINE ATOPIC COMORBIDITIES AND HEALTHCARE RESOURCE UTILIZATION (HCRU) AMONG PATIENTS WITH ATOPIC DERMATITIS (AD) IN THE EUROSTAD PROSPECTIVE OBSERVATIONAL REGISTRY

M. De Bruin-weller⁽¹⁾ - A. E. Pink⁽²⁾ - S. M. Ferrucci⁽³⁾ - P. Arenberger⁽⁴⁾ - Å. Svensson⁽⁵⁾ - M. L. Schuttelaar⁽⁶⁾ - A. Nosbaum⁽⁷⁾ - S. Jayawardena⁽⁸⁾ - L. Eckert⁽⁹⁾ - M. Ardeleanu⁽¹⁰⁾ - A. Sorrentino⁽⁹⁾ - Z. Ozturk⁽⁹⁾

Department Of Dermatology/allergology, University Medical Center Utrecht, Utrecht, Netherlands⁽¹⁾ - St John's Institute Of Dermatology, Guy's & St. Thomas' Hospital, London, United Kingdom⁽²⁾ - Dermatology Unit, Fondazione Irccs Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy⁽³⁾ - Dermatovenerologická Klinika 3, Charles University Of Prague, Prague, Czech Republic⁽⁴⁾ - Department Of Dermatology, Skane University Hospital, Lund University, Malmö, Sweden⁽⁵⁾ - Faculty Of Medical Sciences, University Medical Center Groningen, University Of Groningen, Groningen, Netherlands⁽⁶⁾ - Department Of Allergy And Clinical Immunology, Lyon-sud University Hospital, Pierre-benite Cx, France⁽⁷⁾ - Sanofi, Sanofi, Bridgewater, Nj, United States⁽⁸⁾ - Sanofi, Sanofi, Chilly-mazarin, France⁽⁹⁾ - Regeneron Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Inc., Tarrytown, Ny, United States⁽¹⁰⁾

Introduction: The European Prospective Observational Study in Patients Eligible for Systemic Immunosuppressive Therapy for AD (EUROSTAD) registry follows the characteristics and management of patients with AD in a real-world setting.

Objective: To report baseline comorbidities and HCRU of EUROSTAD.

Materials and Methods: EUROSTAD enrolled patients aged ≥ 18 years eligible to receive systemic therapy for AD including immunosuppressive therapy.

Results: 308 (85.6%) patients with AD were enrolled. 133 (43.2%) patients were female; most patients enrolled from Italy (30.2%). At baseline, mean (standard deviation [SD]) age was 37.19 (13.8) years, and mean body mass index 24.73 (4.9) kg/m². Mean (SD) age of AD onset was 11.82 (16.8) years; mean duration of AD was 25.42 (15.6) years. Most patients had moderate (53.5%) or severe (31.6%) AD (Investigator's Global Assessment score 3 or 4). At enrollment, the current systemic therapy of patients was cyclosporine (40.5%), methotrexate (23.2%), corticosteroids (all; 19.0%), and dupilumab (18.3%). 82.1%





of patients had ≥ 1 relevant medical history/comorbidity; of these patients, 96.0% (n=243) reported ≥ 1 ongoing condition. Comorbidities occurring in $>1\%$ of the enrolled patients were allergic rhinitis (61.7%), asthma (53.3%), allergic conjunctivitis (43.2%), food allergy (38.6%), chronic rhinosinusitis (14.0%), atopic keratoconjunctivitis (8.4%), nasal polyps (4.9%), aspirin sensitivity (4.6%), diabetes type 1/2 (2.3%), and oral herpes (2.3%). HCRU over 12 months before enrollment for reasons related to AD flares/AD but not for flares included a mean (SD) of 5.7 (9.3)/3.1 (4.5) visits to a healthcare professional, 11.4 (25.9)/5.5 (18.8) total days off from usual activities, and 0.2 (0.6)/0.0 (0.3) emergency room admissions. The average out-of-pocket monthly medication costs for most patients were between €0–5 (13.2% of patients), $>€5-10$ (9.7%), $>€10-50$ (29.5%), $>€50-100$ (28.1%), or $>€100-200$ (16.7%).

Conclusions: The EUROSTAD suggests that in a real-world setting, patients with AD have substantial burden of atopic/allergic comorbid conditions and HCRU.

